Solventum Co. (NYSE:SOLV) Shares Sold by Hall Laurie J Trustee

Hall Laurie J Trustee cut its stake in Solventum Co. (NYSE:SOLV) by 11.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,813 shares of the company’s stock after selling 624 shares during the period. Hall Laurie J Trustee’s holdings in Solventum were worth $318,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in SOLV. Merit Financial Group LLC bought a new position in Solventum during the 4th quarter worth approximately $235,000. Wedge Capital Management L L P NC raised its position in shares of Solventum by 7.3% during the 4th quarter. Wedge Capital Management L L P NC now owns 75,283 shares of the company’s stock valued at $4,973,000 after acquiring an additional 5,094 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. lifted its stake in Solventum by 69.7% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 891 shares of the company’s stock worth $59,000 after purchasing an additional 366 shares during the last quarter. Oak Thistle LLC bought a new position in Solventum during the fourth quarter worth $512,000. Finally, Czech National Bank boosted its holdings in Solventum by 6.5% in the fourth quarter. Czech National Bank now owns 29,966 shares of the company’s stock worth $1,980,000 after purchasing an additional 1,820 shares during the period.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Piper Sandler raised their price target on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Mizuho started coverage on shares of Solventum in a report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 target price on the stock. Wolfe Research began coverage on Solventum in a report on Thursday, September 26th. They set a “peer perform” rating for the company. Morgan Stanley raised their price target on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Finally, Stifel Nicolaus started coverage on shares of Solventum in a research report on Tuesday, October 8th. They set a “buy” rating and a $82.00 price target for the company. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, Solventum has a consensus rating of “Hold” and a consensus target price of $68.29.

Solventum Stock Performance

Solventum stock opened at $73.60 on Monday. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05. The firm’s 50 day moving average price is $69.12 and its two-hundred day moving average price is $65.59. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.